

In the Claims

Amend claim 1, as follows:

1. (Currently amended) A method of treating a corticosteroid-responsive disease of the upper, or lower airway passages or of the lungs in patients afflicted with said disease, which comprises comprising administering once a day once daily to the surfaces of said nasal passages or lungs of said patients a substantially non systematically bioavailable amount of aerosolized particles about 400 micrograms of mometasone furoate effective for treating said disease.

Cancel claims 2-29.

Add claims 30-38, as follows:

30. (New) The method of claim 1, wherein the mometasone furoate is administered as anhydrous mometasone furoate.

31. (New) The method of claim 1, wherein the mometasone furoate is administered as mometasone furoate monohydrate.

32. (New) The method of claim 1, wherein the mometasone furoate is administered in the form of an aqueous suspension.

33. (New) The method of claim 1, wherein the mometasone furoate is administered in the form of an aqueous suspension of mometasone furoate monohydrate.

34. (New) The method of claim 1, wherein the mometasone furoate is administered in the form of an aqueous suspension of anhydrous mometasone furoate.

35. (New) The method of claim 1, wherein there are administered 400 micrograms of mometasone furoate by applying four times to each nostril about 50 micrograms of mometasone furoate.

36. (New) A method of treating a corticosteroid-responsive disease, comprising administering once daily to nasal passages an aqueous nasal spray comprising mometasone furoate monohydrate, in an amount providing about 200 micrograms of mometasone furoate to each nostril.

37. (New) The method of claim 36, wherein there are administered 400 micrograms of mometasone furoate by applying four times to each nostril about 50 micrograms of mometasone furoate.